CVS Health beat Wall Street expectations for the quarter ended September 2026, reporting earnings of $2.09 per share on revenue of $108.4 billion. The results gave shareholders a clean headline: profit came in well above the Zacks Consensus Estimate of $1.62 per share, while sales also cleared forecasts.
The earnings surprise was 29.01%, and revenue beat estimates by 3.20%. That matters because CVS had also beaten consensus in each of the last four quarters on both EPS and revenue, a pattern that suggests the latest report was not a one-off.
The move now is in the numbers people were waiting to see. CVS Health had earned $1.6 per share a year earlier and had been expected to post $1.87 per share in the prior quarter before delivering $2.58 per share. Against that backdrop, the new quarter looks like another solid step forward, especially with shares already up about 15.2% since the start of the year, ahead of the S&P 500's 10.6% gain.
But the setup was not uniformly bullish before the report. CVS Health carried a Zacks Rank #3 (Hold), and the estimate-revisions trend was mixed, which kept expectations from running too far ahead of results. The company also sits in the Medical Services group, an industry that is currently in the top 45% of the 250 plus Zacks industries, so the market had some support for the stock even before this print.
What happens next will depend less on the beat itself than on how management frames the quarter on the earnings call. The current outlook already points to $1.26 a share on $107.12 billion in revenue for the coming quarter and $8.02 a share on $418.17 billion in revenue for the fiscal year, so investors will be listening for whether CVS can back up the latest outperformance with guidance that keeps that path intact.
For now, the answer to the question investors were asking is straightforward: CVS Health did beat on both profit and revenue. The harder question is whether the company can turn this quarter's numbers into a clearer case for the stock after a mixed signal from revisions and a hold rating left the market waiting for more than just a headline beat.
